146 related articles for article (PubMed ID: 28764977)
1. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
He J; Huang Y; Liu Z; Zhao R; Liu Q; Wei L; Yu X; Li B; Qin Y
Gene; 2017 Sep; 629():29-34. PubMed ID: 28764977
[TBL] [Abstract][Full Text] [Related]
2. [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
He JY; Liu QY; Wei L; Liu ZJ; Huang Y; Yu XQ; Li B; Qin Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):1-7. PubMed ID: 29737080
[TBL] [Abstract][Full Text] [Related]
3. BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma.
Chen K; Huang W; Huang B; Wei Y; Li B; Ge Y; Qin Y
Genet Test Mol Biomarkers; 2013 Feb; 17(2):160-5. PubMed ID: 23237599
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
5. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of BORIS and SOCS3 in human hepatocellular carcinoma.
Zhao R; Chen K; Zhou J; He J; Liu J; Guan P; Li B; Qin Y
Medicine (Baltimore); 2017 Mar; 96(12):e6420. PubMed ID: 28328845
[TBL] [Abstract][Full Text] [Related]
7. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
[TBL] [Abstract][Full Text] [Related]
8. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
9. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
10. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma.
Zhu C; Utsunomiya T; Ikemoto T; Yamada S; Morine Y; Imura S; Arakawa Y; Takasu C; Ishikawa D; Imoto I; Shimada M
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S729-35. PubMed ID: 24992910
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
14. Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma.
Tanaka Y; Kanda M; Sugimoto H; Shimizu D; Sueoka S; Takami H; Ezaka K; Hashimoto R; Okamura Y; Iwata N; Tanaka C; Yamada S; Fujii T; Nakayama G; Koike M; Nomoto S; Fujiwara M; Kodera Y
Int J Oncol; 2015; 46(6):2546-54. PubMed ID: 25892360
[TBL] [Abstract][Full Text] [Related]
15. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
16. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
17. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma.
Li B; Liu W; Wang L; Li M; Wang J; Huang L; Huang P; Yuan Y
Ann Surg Oncol; 2010 Jul; 17(7):1917-26. PubMed ID: 20112070
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma.
Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Lehmann U
J Pathol; 2014 Aug; 233(4):392-401. PubMed ID: 24838394
[TBL] [Abstract][Full Text] [Related]
20. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
